Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 4 syntheses or guidelines pooled it, 186 citations in OpenAlex.
- Rate of dissemination and prognosis in early and advanced stage colorectal cancer based on microsatellite instability status: systematic review and meta-analysis.International journal of colorectal disease · 2021Pooled it
- Prognostic Value of MicroRNAs in Stage II Colorectal Cancer Patients: A Systematic Review and Meta-Analysis.Molecular diagnosis & therapy · 2020Pooled it
- Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy.BMC cancer · 2015Pooled it
- Prognostic significance of POLE proofreading mutations in endometrial cancer.Journal of the National Cancer Institute · 2015Pooled it
- Toripalimab, bevacizumab, and irinotecan in dMMR/MSI locally advanced colorectal cancer: First-stage results from a phase 1b/2 trial.Cell reports. Medicine · 2025Trial
- Evaluating the utility ofEpigenetics · 2024Trial
- Trial
- CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.Gastroenterology · 2014Trial
- Trial
- Adjuvant Chemotherapy and Survival in MSI-High Stages II and III Colon Cancer: Impact of Histopathologic Risk Stratification.Annals of surgical oncology · 2025Article
- Review
- Review
- Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer.Cell reports. Medicine · 2024Article
- Discovery and validation of a 10-gene predictive signature for response to adjuvant chemotherapy in stage II and III colon cancer.Cell reports. Medicine · 2024Article
- Unraveling the Interplay of KRAS, NRAS, BRAF, and Micro-Satellite Instability in Non-Metastatic Colon Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- The development and implementation of pathological parameters and molecular testing impact prognosis of colorectal adenocarcinoma.Journal of the National Cancer Center · 2024Article
- Radiologic T staging of colon cancer: renewed interest for clinical practice.Abdominal radiology (New York) · 2023Review
- Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era.Cells · 2023Review
- Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape.The Journal of pathology · 2022Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
purposeColorectal cancer (CRC) develops as a result of a series of accumulated genomic changes that produce oncogene activation and tumor suppressor gene loss. These characteristics may classify CRC into subsets of distinct clinical behaviors. PATIENTS AND
methodsWe studied two of these genomic defects-mismatch repair deficiency (MMR-D) and loss of heterozygosity at chromosomal location 18q (18qLOH)-in patients enrolled onto two phase III cooperative group trials for treatment of potentially curable colon cancer. These trials included prospective secondary analyses to determine the relationship between these markers and treatment outcome. A total of 1,852 patients were tested for MMR status and 955 (excluding patients with MMR-D tumors) for 18qLOH.
resultsCompared with stage III, more stage II tumors were MMR-D (21.3% v 14.4%; P < .001) and were intact at 18q (24.2% v 15.1%; P = .001). For the combined cohort, patients with MMR-D tumors had better 5-year disease-free survival (DFS; 0.76 v 0.67; P < .001) and overall survival (OS; 0.81 v 0.78; P = .029) than those with MMR intact (MMR-I) tumors. Among patients with MMR-I tumors, the status of 18q did not affect outcome, with 5-year values for patients with 18q intact versus 18qLOH tumors of 0.74 versus 0.65 (P = .18) for DFS and 0.81 versus 0.77 (P = .18) for OS.
conclusionWe conclude that MMR-D tumor status, but not the presence of 18qLOH, has prognostic value for stages II and III colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.